Sangamo BioSciences (SGMO) Receives Analyst Rating

Sangamo BioSciences (SGMO) : Zacks Investment Research ranks Sangamo BioSciences (SGMO) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 1.33, which indicates as a Strong Buy.

Sangamo BioSciences (SGMO) stock is expected to deviate a maximum of $10.18 from the average target price of $15.25 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $30 and the most muted being $8.


Also, In a research note released to the investors, Janney Capital downgrades its rating on Sangamo BioSciences (NASDAQ:SGMO).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 4, 2016.

Sangamo BioSciences (NASDAQ:SGMO): After opening at $4.72, the stock dipped to an intraday low of $4.625 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $4.745 and the buying power remained strong till the end. The stock closed at $4.72 for the day, a gain of 0.43% for the day session. The total traded volume was 540,008. The stocks close on the previous trading day was $4.7.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *